CIDP – Sanofi EFC18156 VITALIZE

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.

Specific criteria applies.

Complete the form to get connected with new research studies and our team will reach out soon to help determine your eligibility.